Tenofovir-related nephrotoxicity in HIV-infected patients.
Barrios
Ana
A
García-Benayas
Teresa
T
González-Lahoz
Juan
J
Soriano
Vincent
V
D058186:Acute Kidney Injury / Q000139:chemically induced*; D000225:Adenine / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000480:Alkynes; D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D048588:Benzoxazines; D003521:Cyclopropanes; D016049:Didanosine / Q000008:administration & dosage; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1; D006801:Humans; D008297:Male; D008875:Middle Aged; D063065:Organophosphonates; D009943:Organophosphorus Compounds / Q000009:adverse effects* / Q000627:therapeutic use; D010078:Oxazines / Q000008:administration & dosage; D000068698:Tenofovir
D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D063065:Organophosphonates; D009943:Organophosphorus Compounds; D010078:Oxazines; D000068698:Tenofovir; D000225:Adenine; C098320:efavirenz; D016049:Didanosine